Brief: Orphazyme Establishes U.S. Offering Program With Cowen

Strategic Partners A/S

04/11/2021 12:57

Nov 4 (Reuters) - Orphazyme A/S  ORPHA.CO :
    * ORPHAZYME ESTABLISHES A U.S. AT-THE-MARKET OFFERING
PROGRAM WITH
COWEN
    * FILED WITH U.S. SECURITIES AND EXCHANGE COMMISSION
PROSPECTUS
SUPPLEMENT RELATING TO A U.S. AT--MARKET OFFERING PROGRAM
    * MAY ISSUE AND SELL AMERICAN DEPOSITARY SHARES HAVING AN
AGGREGATE OFFERING PRICE OF UP TO $50,000,000,
    * TIMING OF ANY SALES WILL DEPEND ON A VARIETY OF FACTORS.
    * ADSS TO BE SOLD IN  US AT MARKET PRICE, FROM TIME TO TIME,
AT
ITS OPTION, IN "AT MARKET" TRANSACTIONS ON NASDAQ GLOBAL SELECT
MARKET
    * COMPANY EXPECTS TO USE NET PROCEEDS FROM SALES OF ANY ADSS
PURSUANT TO ATM PROGRAM TO CONTINUE REGULATORY APPROVAL PROCESS
FOR AND FUND COMMERCIAL LAUNCH, IF APPROVED, OF ARIMOCLOMOL FOR
TREATMENT OF NIEMANN-PICK DISEASE TYPE C AND FOR WORKING CAPITAL
AND GENERAL CORPORATE PURPOSES.
    * ADSS ARE INTENDED TO BE SOLD PURSUANT TO A SALES AGREEMENT
(
"SALES AGREEMENT") WITH COWEN AND COMPANY,
    * TIMING OF ANY SALES WILL DEPEND ON A VARIETY OF FACTORS.

Source text for Eikon:  ID:nGNEWsCh4 
Further company coverage:  ORPHA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))